Eight patients with severe bronchopulmonary dysplasia underwent cardiac catheterisation. Seven had a pulmonary vascular resistance >3 mm Hg.l-' min.m2 (mean 8-9, range 2-2-13-8). All had raised intrapulmonary shunts (mean 25-6%, range 5-4-50%, normal <5%). Two had a high alveolar dead space, and two had unsuspected congenital heart disease. Epoprostenol (prostacyclin), but not 100% oxygen, caused a significant fail in pulmonary vascular resistance. Death was associated with a high pulmonary vascular resistance and a high shunt. Morphometric studies in three cases showed normal numbers of airways, but increased thickness of bronchial muscle. The numbers of alveoli were reduced and the wails thickened. There was increased medial thickness in small pulmonary arteries with distal extension of muscle. In the oldest child some vessels were obliterated by fibrosis. We speculate that measurements of pulmonary vascular resistance and shunt may have prognostic value; that a trial of pulmonary vasodilators other than oxygen might be worthwhile in patients with poor prognosis; and that abnormalities of the pulmonary circulation contribute to the difficulties of managing patients with bronchopulmonary dysplasia.
. All had raised intrapulmonary shunts (mean 25-6%, range 5-4-50%, normal <5%). Two had a high alveolar dead space, and two had unsuspected congenital heart disease. Epoprostenol (prostacyclin), but not 100% oxygen, caused a significant fail in pulmonary vascular resistance. Death was associated with a high pulmonary vascular resistance and a high shunt. Morphometric studies in three cases showed normal numbers of airways, but increased thickness of bronchial muscle. The numbers of alveoli were reduced and the wails thickened. There was increased medial thickness in small pulmonary arteries with distal extension of muscle. In the oldest child some vessels were obliterated by fibrosis. We speculate that measurements of pulmonary vascular resistance and shunt may have prognostic value; that a trial of pulmonary vasodilators other than oxygen might be worthwhile in patients with poor prognosis; and that abnormalities of the pulmonary circulation contribute to the difficulties of managing patients with bronchopulmonary dysplasia. Accepted 28 February 1990 The aggressive treatment of low birthweight, premature infants with respiratory distress has been extremely successful, but the cost has been that some survivors are left with chronic lung disease. Bronchopulmonary dysplasia was first described in 1967,' and is now increasingly recognised as a major cause of respiratory disability in infants. 2 3 There have been many studies of airway function4 5 and lung mechanics,6 7 but the cardiovascular consequences of bronchopulmonary dysplasia have received less attention, 4 [8] [9] [10] [11] [12] despite the recognition of the prognostic importance of cor pulmonale in the earliest descriptions of the disease. ' The Brompton Hospital is a tertiary referral centre for infants with severe bronchopulmonary dysplasia. Infants referred to the department of paediatric cardiology undergo cardiac catherterisation, mainly to exclude clinically important cardiac structural defects. At the same time we assess the response of the pulmonary circulation to vasodilators to see if they might be beneficial. We describe here the pulmonary haemodynamics and the abnormalities in gas exchange in this selected group, correlating them with quantitative lung morphology when possible. 16 Briefly, the infants were studied while they were anaesthetised, paralysed, and ventilated. We measured cardiac output by the direct Fick principle, and calculated pulmonary vascular resistance, wasted ventilation (alveolar dead space), and wasted perfusion (anatomical shunt). We assessed the fall in pulmonary vascular resistance in response to administration of 100% oxygen and to prostacyclin given intravenously.
For the calculations of cardiac output, oxygen consumption was measured by a mass spectrometer (MGA 200) using the steady state, argon dilution method.'5 Blood oxygen contents were calculated from measured PaO2, pH, and base excess (Corning 170 blood gas analyser), using Kelman's subroutine and assuming the solubility of free oxygen in blood to be 0-003 ml/100 ml/mm Hg.'7 The mass spectrometer was also used to monitor end tidal gases to ensure a respiratory steady state was maintained throughout the study. End tidal PCO2 was calculated as the mean of at least eight measurements, which had to differ by less than 05 kPa (3) (4) (5) (6) (7) (8) (twice the wall thickness/external diameter). The extension of muscle along the arterial pathway was determined. For the airways, the diameter of small bronchi and bronchioli was measured. The amount of bronchial wall muscle was estimated by planimetry using the Kontron MOP Videoplan image analyser, and expressed for each airway as area in mm2/mm length of lumen. The number of alveoli in the acinar region was estimated by calculating the Emery count. '9 Results There were four boys and four girls, mean age 12 months, range 10 weeks to 3 years (table 1) . At the time of cardiac catherisation, cases 1-7 were being treated for cor pulmonale, which had been diagnosed on clinical grounds. All were receiving diuretics (frusemide and spironolactone) and cases 1-3 and case 5 were receiving digoxin. There was only one long term survivor; cases 1, 2, 6, and 7 died of progressive cardiorespiratory failure associated with presumed bronchopulmonary sepsis. In case 1, Candida albicans was isolated from the nasopharyngeal aspirate. In the other infants the diagnosis was a clinical one, but no pathogenic organisms were isolated. Case 3 died after aspirating a feed, and case 4 died in the intensive care unit of intractable pulmonary hypertension. The deaths were attributed to the complications of bronchopulmonary dysplasia, not to the haemodynamic studies. Case 8, whose main problem was congenital heart disease, had surgical correction of the anomalous vena cava, but died after a stormy postoperative course complicated by recurrent pulmonary oedema, infection, and renal failure. Prostacyclin Prostacyclin Prostacyclin Figure 5 Percentage changes over baseline (vertical axis) in pulmonary haemodynamics with 100% oxygen (02) and the dose ofprostacyclin resulting in the lowest pulmonary vascular resistance. There was no significant change in pulmonary artery pressure; cardiac output rose, and pulmonary vascular resistance fell when prostacyclin was given. These results are from thefive patients with complete data for all doses ofprostacyclin (case numbers 1-3, 5, and 6). Bar indicate mean (SEM) and significant differences are indicated.
measurement. Figure 5 shows that there was no significant change in pulmonary artery pressure at any time, and (for the group) no significant change in any variable when breathing 100% oxygen. Cardiac output (mean (95% confidence intervals)) rose by 30-8 (18-8 to 42-8)% when prostacyclin was added to oxygen, and pulmonary vascular resistance fell by 23-2 (9-1 to 37-3)%. Prostacyclin also had effects on the systemic circulation (fig 6) . There was no change in aortic pressure, but systemic vascular resistance fell by 38-8 (13-8 to 63 8)%, and heart rate rose by 11 0 (3-9 to 18-1)%, when prostacyclin was added to oxygen; from these data, there was no evidence for any selective effect on the pulmonary circulation.
Of the six patients who died with severe bronchopulmonary dysplasia (cases 1-4, 6, and 7), two had pulmonary vascular resistance of more than 7 units, two had anatomical shunts of more than 30%, and two had both these abnormalities. Both patients with wasted ventilation of more than 25% died.
PATHOLOGICAL STUDIES
In cases 2, 3, and 6 the structure of the peripheral airways and alveoli was abnormal, the alveoli varying in size and shape. The alveolar walls were thickened with an excess of collagen and elastin, and in cases 2 and 3 capillary density seemed to be increased. In all three cases, an Emery count indicated a reduction in alveolar number (table 2). In the oldest, aged 3 years, the alveolar count was similar to the normal value at birth. The peripheral airways were of normal size for age, but the amount of bronchial smooth muscle was increased. There were no areas of extensive fibrosis. In the vasculature, pulmonary arterial smooth muscle was increased, as shown by a significant increase in mean percentage arterial medial thickness and by extension of muscle into more peripheral arteries than normal so that most of the alveolar wall arteries were completely muscularised (table 2, fig 7) . Only the oldest case showed intimal proliferation, with hyalinisation of the the left atrium, was thought to have severe bronchopulmonary dysplasia before the haemodynamic study. At necropsy, however, she had none of the pathological features. The Emery count indicated that the number of alveoli was within normal limits and the airways were of normal size and muscularity (table 2). The significant increases in pulmonary arterial and vein wall thickness were compatible with the cardiac anomalies present in this child.
Discussion
We have reported eight patients who were sent to a-tertiary referral centre with a diagnosis of severe bronchopulmonary dysplasia. One patient (case 8) was cyanosed because of a cardiac structural lesion, and histology of the lung confirmed only minor changes of bronchopulmonary dysplasia. Similar diagnostic difficulties have been reported by others,9 and it may be difficult to assess clinically the relative severity of heart and lung disease. This patient is not discussed further. The main findings in the other seven patients were increases in pulmonary vascular resistance (n=7), anatomical shunt (n=2), and alveolar dead space (n=2). In this selected group of patients, prostacyclin was a better pulmonary vasodilator than oxygen. The patients with pulmonary vascular resistance of greater than 7 units, or anatomical shunt of more than 30%, or both (n=6), died from their disease. Quantitative histology (n=3)
showed reduced numbers of alveoli with thickened walls. There was increased medial muscle thickness in small pulmonary arteries, and distal extension of smooth muscle. The changes tended to be more severe with increasing age and pulmonary vascular resistance, although there were too few infants for statistical testing.
The physiological study compared the pulmonary vascular reactivity to oxgyen and prostacyclin. We chose prostacyclin because we had previously shown it to be a safe pulmonary vasodilator in children with congenital heart disease.16 Oxygen has been reported to lower pulmonary vascular resistance in some but not all patients with bronchopulmonary dysplasia. 10 1 In our selected group of patients, oxygen had no acute effects on pulmonary haemodynamics, whereas prostacyclin caused a pronounced fall in pulmonary vascular resistance. Other workers have reported falls in pulmonary vascular resistance in patients with bronchopulmonary dysplasia given hydralazine.12 We recommend extreme caution, however, if prostacycin or other bloodborne pulmonary vasodilators are to be used. Case 4 was unable to tolerate a dose higher than 10 ng/kg/ min because of systemic hypotension. Prostacyclin caused a fall in systemic vascular resistance in all patients, and a fall in PaO2 in two. Hydralazine may also cause adverse reactions in patients with bronchopulmonary dysplasia. 12 Under controlled conditions, bloodborne pulmonary vasodilators may be useful adjuncts to management, and possibly allow reductions in inspired oxygen tension, one of the major aetiological factors in bronchopulmonary dysplasia.
The structural study showed that in three cases the abnormalities of the airways consisted of a failure of alveolar multiplication with an increase in both the amount of bronchial smooth muscle, and in the amounts of collagen and elastin within the alveolar walls. These abnormalities of airways were no more severe, however, than those reported, in a previous series of children who also had neonatal respira- Although ours is a small series, the severity of the pulmonary arterial changes tended to increase with age, as shown by the progressive increase in pulmonary vascular smooth muscle, and the presence of some hyalinised arteries in the oldest child. Correlation between structure and function is difficult because of the small number of cases and the relatively long time interval (up to nine months) between cardiac catheterisation and death in these young patients. The wasted perfusion might be the result of collagen deposition in the alveolar walls, and possibly also in the blood gas barrier.28 Wasted ventilation could be attributed to a reduction in peripheral pulmonary arterial number and the diameters of the lumens.
These data were obtained from a highly selected subgroup of patients with bronchopulmonary dysplasia, but may have implications for the outpatient treatment of less severely affected patients. The current mainstay of treatment is domiciliary oxygen. 29 30 Treatment with an oral pulmonary vasodilator would be much more convenient than low flow oxygen. Theoretically it may even be safer, in that there is some evidence that even modest increases in inspired oxygen tensions may be toxic.3' 32 Any fall in PaO2 would be dangerous, however, in patients who have arterial hypoxaemia while breathing air, because a large fall in blood oxygen content would result. Possibly the combination of low flow oxygen and an oral vasodilator might be more useful than either alone. If they are to affect the natural history of the disease appreciably, however, they would probably have to be given much earlier, before the pulmonary circulation became irreversibly damaged. Any such treatment should be the subject of a carefully controlled trial before it could be recommended for general use.
To summarise, we have reported the pulmonary circulatory abnormalities in eight patients referred with a clinical diagnosis of bronchopulmonary dysplasia. In this selected group, pulmonary vascular disease showed itself physiologically by an increased pulmonary vascular resistance and by disturbances of ventilation to perfusion matching. The increases in pulmonary vascular resistance were reduced more by a bloodborne vasodilator, prostacyclin, than by 100% oxygen. In these patients the morphological counterpart was failure of alveolar multiplication and consequent hypoplasia of the pulmonary circulation, extensive muscularisation of precapillary arteries and peripheral veins, and some obliteration of vessels by fibrosis in case 6. Most of these developmental changes are probably irreversible, although a reduction in muscularity is possible. The reason why some patients develop severe pulmonary vascular disease secondary to bronchopulmonary dysplasia is not clear. We suggest that cardiac catheterisation should be carried out more readily in patients with bronchopulmonary dysplasia. It is important to exclude cardiac structural lesions, and hyperinflation may make echocardiography difficult. Cardiac catheterisation may also help to choose the most effective treatment for the individual patient. In addition, we need to increase our understanding of the role of the pulmonary circulation in the pathogenesis of this condition. bronchopulmonary dysplasia. 
Changes in pulmonary circulation in severe

